DiaMedica Therapeutics Inc.DMACNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating

Buy

6 analysts·Limited coverage

100%

Rating Distribution

Strong Buy

00%

Buy

6100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Current price is 0% above analyst consensus — near fair value expected.

Bear Case

$7.00

-16%

Consensus

$8.33

-0%

Bull Case

$10.00

+20%

Price Range6 analysts

Low

Consensus

High

$7.00

$10.00

Current Target

Current Price

$8.35

Above Target

$0.02

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.76(4 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-94.84%

EPS—

FY2028

Rev+404.09%

EPS—

FY2029

Rev+181.90%

EPS—

Earnings Surprises

Beat rate:33%(4/12 quarters)

Avg surprise:+2.4%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Oct 7, 2024Truist Financial

This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Target:$10.00

+126.5%from $4.42

Oct 7, 2024H.C. Wainwright

DiaMedica Therapeutics initiated with a Buy at H.C. Wainwright

Target:$7.00

+60.6%from $4.36

Mar 21, 2024Craig-Hallum

DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $8 at Craig-Hallum

Target:$8.00

+197.4%from $2.69

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance